Is tpst stock good to buy right now

**Tempest Therapeutics (TPST) stock does not appear to be a good buy at the moment.** Here's why:

1. **Recent Surge in Stock Price**: TPST stock has seen a significant increase, with a 44.8% rise on the day of the announcement of new data from the Phase 1b/2 clinical trial of amezalpat. This is largely due to investor excitement over the six-month improvement in median overall survival advantage shown by amezalpat when combined with atezolizumab and bevacizumab.

|Ticker|Name|Support Level|Resistance Level|Closing Price|Date|code|market_code|
|---|---|---|---|---|---|---|---|
|TPST.O|Tempest Therapeutics|2.0800|2.1850|2.12|20240702|TPST|186|

2. **Technical Indicators Suggest Caution**: The stock's technical indicators show a 5-day moving average of $2.16, a 10-day moving average of $2.18, and a 50-day moving average of $3.10. The RSI is at 24.85, which is considered to be in the oversold territory but also suggests that the stock may be undervalued. The MACD is -0.07, indicating a bearish trend, and the Bollinger Bands show a lower band at 2.66, which could be a support level.

|Ticker|Name|50-Day Moving Average|5-Day Moving Average|10-Day Moving Average|Date|code|market_code|
|---|---|---|---|---|---|---|---|
|TPST.O|Tempest Therapeutics|3.0957|2.1560|2.1820|20240702|TPST|186|

|Ticker|Name|RSI|MACD|KDJ|Boll|Date|code|market_code|
|---|---|---|---|---|---|---|---|---|
|TPST.O|Tempest Therapeutics|24.8474|-0.0704|31.4827|2.6555|20240702|TPST|186|

3. **Financial Performance**: The company has reported a net loss of $7.9 million and a negative ROE of -33.35% as of the last quarter. This financial performance indicates that the company is currently unprofitable and may not be in a strong financial position.

|Ticker|Name|Total Revenue|ROE(Average)|Net Income|Gross Profit Margin|Dividend Yield (TTM)|Diluted EPS|Date|code|market_code|
|---|---|---|---|---|---|---|---|---|---|---|
|TPST.O|Tempest Therapeutics||-33.3502|-7904000|||-0.36|20240331|TPST|186|
|TPST.O|Tempest Therapeutics|||||||20240702|TPST|186|

4. **Analyst Price Targets**: Analysts have set a 12-month price target for TPST at an average of $21.68, with a high estimate of $49.35. However, it's important to note that these targets are based on projections and may not always be accurate.
5. **Market Sentiment**: The sentiment around TPST is generally bearish, with a fear and greed index of 39 (Fear) and a recent stock forecast predicting a drop in price. This suggests that investors may be cautious or pessimistic about the stock's future performance.

In conclusion, while the recent positive data from the clinical trial could be a positive sign, the current surge in stock price, combined with the bearish technical indicators and the company's financial performance, suggests that TPST stock may not be a good buy at the moment. Investors should exercise caution and consider these factors before making any investment decisions.